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Research letter
Oral prednisolone for 4 days does not
increase exercise tolerance in men
with COPD
SL Karlsson1, V Backer2 and Nina Skavlan Godtfredsen1
Abstract
One of the primary objectives in management of chronic obstructive pulmonary disease (COPD) is
preventing decrease in lung function and reducing the annual number of acute exacerbations of COPD
(AECOPD). An oral course of systemic corticosteroids is a commonly used treatment in AECOPD. We
hypothesize that this treatment also increases exercise performance and decreases muscle fatigue. In a
randomized double-blinded, parallel, placebo-controlled trial, we investigated 14 men (8 on prednisolone
37.5 mg vs. 6 on placebo) with severe and very severe COPD. For 5 consecutive days, the patients
performed a submaximal endurance test measuring time to exhaustion (TTE, primary endpoint),
spirometry, maximal inspiratory and expiratory pressure and maximal isometric contraction of the
quadriceps femoris muscle (maximum voluntary contraction (MVC)). At visits 2, 3 and 4, a fatigue
protocol was carried out after 40 minutes of cycling at 40% of maximal effort. No differences between
groups were found for TTE, lung function or maximal inspiratory or expiratory pressure, however, patients
on prednisolone showed significant increased MVC: median 5.15 [3.35; 9.15] against placebo: 2 [5.57;
3.95] (p ¼ 0.03). This finding indicates an impact of corticosteroids on muscle groups being exposed to
submaximal endurance.
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Although oral corticosteroids are not recommended
in stable chronic obstructive pulmonary disease
(COPD), there is evidence of a subjective feeling
of well-being among patients with COPD, a term
often referred to as steroid euphoria.1 This subjective
benefit has however not shown to improve the max-
imal oxygen consumption (VO2max) in COPD
patients.2 One study confirmed the effect of corticos-
teroids in healthy individuals by administering
60 mg of prednisolone daily for 7 days, showing an
increased time to exhaustion (TTE) at 70–75% of
VO2max.
3 The mechanisms might be attributed to
an impaired sensation of fatigue, reduced muscle
inflammation after exercise or to increased
availability of metabolic substrates during exercise
(glucose and free fatty acids).4 The aim of this study
was to investigate whether 4 days of oral
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corticosteroids could preserve or increase exercise
tolerance and muscle strength in stable COPD
patients after performing a fatigue protocol.
The study was a randomized, double-blinded, par-
allel design with eight participants receiving 37.5 mg
of prednisolone and six participants receiving pla-
cebo. Approval was obtained from local and national
ethics committees (nos H-3-2012-142/ EudraCT
2012-004503-13). The study consisted of six visits:
one baseline visit 5–7 days before five consecutive
daily visits. At the baseline visit, eligibility was deter-
mined, and spirometry, body plethysmography,
COPD Assessment Test (CAT), diffusion capacity
(DLCO) and an incremental exercise test were per-
formed. At visit 1, spirometry, CAT and maximal
inspiratory/expiratory pressure (MIP/MEP) were
assessed followed by a 5-minute warm up at 10%
Wmax and 20 minutes at 40% Wmax. A maximum vol-
untary contraction (MVC) of the quadriceps muscle
on the participant’s leading leg was then followed.
After 5 minutes’ recovery, participants performed a
submaximal exercise test (SMET) at 70% Wmax
according to ERS guidelines5 to measure TTE. At
visits 2, 3 and 4, participants performed a 5-minute
warm up at 10% Wmax followed by two constant
workload cycling tests at 40% Wmax of 20 minutes
separated by 4 minutes’ recovery. On visit 5, partici-
pants performed the same protocol as on visit 1. At
visits 2, 3, 4 and 5, participants were instructed to take
the investigated medicinal product 3 hours before the
study visit (Figure 1). For the statistical analysis,
students t-tests and Mann–Whitney U tests were
performed using SPSS (IBM, Version 19.0).
Of the 16 screened patients, 14 were randomized
and 2 were excluded. Baseline characteristics are
presented in Table 1. Nine patients were on LAMA,
two on LABA, nine on LABA/ICS, nine on SABA,
two on SAMA/SABA, one on ICS monotherapy, one
on phosphodiesterase inhibitors and only one was a
current smoker. No difference was found in TTE
between the prednisolone and the placebo group
p ¼ 0.88 (Table 2), however, both groups showed
improvements in TTE from visit 1 to visit 5 (data not
shown). For the secondary outcomes, there were no
significant changes either except for MVC, which
was significantly higher in the prednisolone group
(p ¼ 0.03).
The observed improvement in the SMET in this
study is probably due to familiarization with the
procedure. Accordingly, the TTE on visit 5 might
represent the participants’ most accurate exercise
tolerance. In previous studies using the SMET, the
majority of participants had mild to moderate COPD,5
whereas the patients in this study had very low lung
function and were not accustomed to strenuous exer-
cise. Although not powered, the MVC was signifi-
cantly lower on visit 5 in the placebo group than in
the prednisolone group, indicating an increase in
muscle strength following the 3 days’ cycling. This
finding is in accordance with a previous study.6
Figure 1. Flowchart of the study.
Table 1. Baseline characteristics of the included patients.
N ¼ 14 Mean SD
FEV1, l 1.02 0.46
FEV1, % 30.55 12.8
FVC, l 2.44 0.79
FVC, % 56.71 15.29
FEV1/FVC, % 41.49 11.8
RV, l 4.96 1.37
RV, % 201.8 61.7
TLC, l 8.52 1.57
TLC, % 119.4 22.1
RV/TLC, % 57.4 8.3
DLCO SB 4.43 1.48
DLCO VA 0.89 0.30
BMI 23.6 4.8
Pack years 44 18.9
CAT score 14 5.2
Age 62.7 6.71
VO2max 15.86 4.43
Wmax 75.0 27.6
SD: standard deviation; FEV1: forced expiratory volume in 1
second; FVC: forced vital capacity; RV: residual volume; TLC:
total lung capacity; DLCO/VA: diffusing capacity of the lung for
carbon monoxide/alveolar volume; BMI: body mass index;
COPD: chronic obstructive pulmonary disease; CAT: COPD
Assessment Test; SB: single breath; VO2max: maximal oxygen
consumption; Wmax: maximal work load at the incremental
test.
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Future studies are warranted for evaluation of the
effect of short-term systemic corticosteroid in cardi-
opulmonary measures of strenuous exercise in severe
and very severe COPD.
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Table 2. Results of the primary and secondary outcomes after the study.
Delta values Prednisolone N ¼ 7 Placebo ¼ 5
p Valuev5–v1 Median [CI 25–75] Median [CI 25–75]
FEV1, l 0.01 [0.03; 0.01] 0.0 [0.5; 0.1] 0.07
FEV1, % predicted 1.0 [2.0; 0.0] 0.0 [1.5; 3.0] 0.18
FVC, l 0.014 [0.21; 0.05] 0.15 [1.0; 0.39] 0.03a
FVC, % predicted 4.0 [4.0; 1.0] 3.0 [2.5; 9.5] 0.03a
MIP 6.0 [20.0; 4.0] 5.0 [3.0; 9.5] 0.054
MEP 4.0 [11.0; 20.0] 7.0 [10.0; 3.0] 0.37
CAT 2 [3.0; 1.0] 1.0 [2.0; 1.5] 0.22
BORG dyspnea 0 [1.0; 1.0] 0.0 [1.5; 1.5] 0.95
BORG leg discomfort 1 [0.0; 1.0] 2.0 [3.0; 9.5] 0.83
TTE 51 [13; 110] 13 [18; 208] 0.88
MVC 5.15 [3.35; 9.15] 2 [5.57; 3.95] 0.03a
CI: confidence interval; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; MIP: maximal inspiratory pressure; MEP:
maximal expiratory pressure; COPD: chronic obstructive pulmonary disease; CAT: COPD Assessment Test; TTE: time to exhaustion;
MVC: maximal voluntary contraction.
aSignificant difference between active and placebo group.
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